HUE070846T2 - CDK4 gátló szilárd formái - Google Patents
CDK4 gátló szilárd formáiInfo
- Publication number
- HUE070846T2 HUE070846T2 HUE21783049A HUE21783049A HUE070846T2 HU E070846 T2 HUE070846 T2 HU E070846T2 HU E21783049 A HUE21783049 A HU E21783049A HU E21783049 A HUE21783049 A HU E21783049A HU E070846 T2 HUE070846 T2 HU E070846T2
- Authority
- HU
- Hungary
- Prior art keywords
- solid forms
- cdk4 inhibitor
- cdk4
- inhibitor
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE070846T2 true HUE070846T2 (hu) | 2025-07-28 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE21783049A HUE070846T2 (hu) | 2020-09-15 | 2021-09-13 | CDK4 gátló szilárd formái |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230357211A1 (enExample) |
| EP (2) | EP4214202B1 (enExample) |
| JP (2) | JP7260606B2 (enExample) |
| KR (1) | KR20230069983A (enExample) |
| CN (1) | CN116507620B (enExample) |
| AU (1) | AU2021345531B2 (enExample) |
| CA (1) | CA3195063A1 (enExample) |
| DK (1) | DK4214202T3 (enExample) |
| ES (1) | ES3022913T3 (enExample) |
| FI (1) | FI4214202T3 (enExample) |
| HU (1) | HUE070846T2 (enExample) |
| MX (1) | MX2023003054A (enExample) |
| PL (1) | PL4214202T3 (enExample) |
| PT (1) | PT4214202T (enExample) |
| SI (1) | SI4214202T1 (enExample) |
| TW (2) | TW202334125A (enExample) |
| WO (1) | WO2022058871A1 (enExample) |
| ZA (1) | ZA202303655B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114667147B (zh) | 2019-08-26 | 2024-09-06 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 |
| US20250041298A1 (en) * | 2021-12-02 | 2025-02-06 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| EP4561571A1 (en) | 2022-07-29 | 2025-06-04 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| US12338248B2 (en) | 2023-07-21 | 2025-06-24 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| KR102587758B1 (ko) * | 2016-07-13 | 2023-10-12 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
| RS61934B1 (sr) | 2016-08-15 | 2021-07-30 | Pfizer | Inhibitori piridopirimdinona cdk2/ 4/6 |
| EP3784664B1 (en) * | 2018-04-26 | 2025-02-19 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
-
2021
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116507620A (zh) | 2023-07-28 |
| SI4214202T1 (sl) | 2025-05-30 |
| EP4214202A1 (en) | 2023-07-26 |
| PL4214202T3 (pl) | 2025-05-19 |
| TW202216698A (zh) | 2022-05-01 |
| MX2023003054A (es) | 2023-04-05 |
| TWI809503B (zh) | 2023-07-21 |
| CA3195063A1 (en) | 2022-03-24 |
| JP7291839B2 (ja) | 2023-06-15 |
| DK4214202T3 (da) | 2025-03-31 |
| JP7260606B2 (ja) | 2023-04-18 |
| TW202334125A (zh) | 2023-09-01 |
| EP4214202B1 (en) | 2025-02-26 |
| AU2021345531A1 (en) | 2023-04-20 |
| JP2022186995A (ja) | 2022-12-15 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4578450A2 (en) | 2025-07-02 |
| BR112023004713A2 (pt) | 2023-04-18 |
| JP2022049005A (ja) | 2022-03-28 |
| KR20230069983A (ko) | 2023-05-19 |
| PT4214202T (pt) | 2025-04-11 |
| ES3022913T3 (en) | 2025-05-29 |
| CN116507620B (zh) | 2025-11-18 |
| AU2021345531B2 (en) | 2024-02-29 |
| ZA202303655B (en) | 2024-09-25 |
| WO2022058871A1 (en) | 2022-03-24 |
| FI4214202T3 (fi) | 2025-04-25 |
| EP4578450A3 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202303655B (en) | Solid forms of a cdk4 inhibitor | |
| IL287668A (en) | Crystalline forms of btk inhibitor | |
| IL287630A (en) | Solid forms of glyt1 inhibitor | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| GB202008201D0 (en) | Inhibitor compounds | |
| IL313548A (en) | MET kinase inhibitors | |
| IL324105A (en) | Processes for preparing a kinase inhibitor | |
| GB202004960D0 (en) | Inhibitor compounds | |
| IL313359A (en) | Solid state forms of FGFR inhibitor | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| SMT202500313T1 (it) | Forme solide di un inibitore di rock | |
| IL319336A (en) | Pharmaceutical forms of CD73 inhibitor | |
| IL288982A (en) | Macrocyclic kinase inhibitor polymorphs | |
| IL291368A (en) | Inhibits expression of methadherin | |
| GB202110373D0 (en) | Inhibitor compounds | |
| HK40096368A (zh) | Cdk2抑制剂的固体形式 | |
| HK40060380A (en) | Solid forms of a glyt1 inhibitor | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB202307924D0 (en) | Inhibitor compounds | |
| GB202306601D0 (en) | Inhibitor compounds | |
| GB202300881D0 (en) | Inhibitor compounds | |
| GB202215245D0 (en) | Inhibitor compounds | |
| GB202207972D0 (en) | Inhibitor compounds | |
| HK40073322A (en) | Polymorphs of a macrocyclic kinase inhibitor |